Trabectedin
- Generic Name
- Trabectedin
- Brand Names
- Yondelis
- Drug Type
- Small Molecule
- Chemical Formula
- C39H43N3O11S
- CAS Number
- 114899-77-3
- Unique Ingredient Identifier
- ID0YZQ2TCP
- Background
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machin...
- Indication
用于治疗急性淋巴母细胞白血病、晚期软组织肉瘤及复发卵巢癌。
- Associated Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Platinum Sensitive Relapsed Ovarian Cancer, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
- Associated Therapies
- -
Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- PharmaMar, Spain
- Target Recruit Count
- 130
- Registration Number
- NCT02367924
- Locations
- 🇩🇪
Medizinische Hochschule Hannover - Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Hannover, Niedersachsen, Germany
🇩🇪Gemeinschaftspraxis Dr. Reichert, Dr. Janssen, Westerstede, Niedersachsen, Germany
🇩🇪Onkologisches Zentrum Donauwörth, Donauwörth, Bayern, Germany
Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin
- Conditions
- Interventions
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 120
- Registration Number
- NCT02359474
- Locations
- 🇩🇪
Helios Klinikum Berlin-Buch, Berlin, Germany
🇩🇪Ludwig-Maximilians University of Munich, Klinikum Großhadern, Munich, Bavaria, Germany
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
- Conditions
- Interventions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Target Recruit Count
- 199
- Registration Number
- NCT02275286
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milan, Italy
🇮🇹Centro di Referimento Ocologico, Aviano, Italy
🇮🇹Candiolo Cancer Institute, Candiolo, Italy
Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2017-12-06
- Target Recruit Count
- 168
- Registration Number
- NCT02249702
- Locations
- 🇮🇹
Policlinico Umberto I, Roma, RM, Italy
🇮🇹Ospedale Sant'Anna, Como, Italy
🇮🇹Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 105
- Registration Number
- NCT02247544
- Locations
- 🇮🇹
Azienda Ospedaliera Sant'Anna, Como, CO, Italy
🇮🇹IRST IRCCS Meldola, Meldola, FC, Italy
🇮🇹A.O. Spedali Civili, Brescia, BS, Italy
Trabectedin for Recurrent Grade II/III Meningioma
- Conditions
- Interventions
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2019-02-28
- Target Recruit Count
- 90
- Registration Number
- NCT02234050
- Locations
- 🇦🇹
Landesnervenklinik Wagner Jauregg, Linz, Austria
🇧🇪U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium
🇧🇪CHU Dinant Godinne - UCL Namur, Yvoir, Belgium
ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2020-01-23
- Target Recruit Count
- 145
- Registration Number
- NCT02194231
- Locations
- 🇮🇹
Istituto Oncologico Veneto - IOV, Padova, PD, Italy
🇮🇹P.O. Spedalli Civili, Brescia, BS, Italy
🇮🇹Istituto Clinico Humanitas, Rozzano, MI, Italy
Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 110
- Registration Number
- NCT02131480
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France
Trabectedin First Line Therapy In Unfit Sarcoma Study
- Conditions
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2018-04-11
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 24
- Registration Number
- NCT02066675
- Locations
- 🇮🇹
Ospedali Riuniti di Bergamo, Bergamo, BG, Italy
🇮🇹Ospedale Galliera, Genova, Genovs, Italy
🇮🇹I.R.C.C. - Unit of Medical Oncology, Candiolo, Torino, Italy
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 581
- Registration Number
- NCT01846611
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.